Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Invesco S&P 500 Equal Weight Health Care ETF

Broadly speaking, the healthcare sector's returns in 2022 are middling. In theory, that shouldn't be the case because the group usually isn't vulnerable to two of the scenarios plaguing markets today: high inflation and Russia's war against Ukraine.

Value Lurks in Healthcare Sector

San Francisco, California--(Newsfile Corp. - April 7, 2022) - Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: June 7, 2021 - Jan. 11, 2022Lead Plaintiff Deadline: April 8, 2022Visit: www.hbsslaw.com/investor-fraud/BIIBContact An Attorney Now: BIIB@hbsslaw.com844-916-0895Biogen Inc. (BIIB) Securities Class Action: The lawsuit focuses on Biogen's and senior manag

BIIB FINAL DEADLINE: Hagens Berman, National Trial Attorneys, Alerts Biogen Inc. (BIIB) Investors to Tomorrow's Lead Plaintiff Deadline

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 6, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and reminds investors of the April 8, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $200,000 investing in Biogen stock or options between...

Biogen Update

San Francisco, California--(Newsfile Corp. - April 5, 2022) - Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: June 7, 2021 - Jan. 11, 2022Lead Plaintiff Deadline: April 8, 2022Visit: www.hbsslaw.com/investor-fraud/BIIBContact An Attorney Now: BIIB@hbsslaw.com844-916-0895Biogen Inc. (BIIB) Securities Class Action: The lawsuit focuses on Biogen's and senior management'

BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firm's Attorneys

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 5, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and reminds investors of the April 8, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $200,000 investing in Biogen stock or options between...

Biogen Class Action Reminder

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies being presented at the American Academy of Neurology (AAN) 2022 Annual Meeting. The presentations include new real-world, long-term data on TYSABRI® (natalizumab), as well as persistence and adherence learnings with VUMERITY® (diroximel fumarate). Additional presentations highlight the use of digital tools to potentially predict MS disease progression. These data build on ongoing work to advance the understanding and treatment of serious neurological and neurodegenerative diseases, and highlight Biogen's commitment to science that strives to address the diverse needs of people living with MS.

New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression

Generic sales hit MS franchise and Alzheimer's treatment is slow starter: EPS forecasts down 20%

Bear of the Day: Biogen (BIIB)

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.

Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May

Biogen Inc. BIIB, +1.54% said Wednesday it submitted the study protocol to the Food and Drug Administration for a confirmatory clinical trial for Aduhelm, its Alzheimer's disease drug. The regulator approved Aduhelm a year ago under the condition that a confirmatory trial would be conducted.

Biogen submits Phase 4 study protocol for Alzheimer's disease drug

CAMBRIDGE, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration (FDA) for review and approval. This is in line with the company's commitment to accelerate the timelines for the trial, including submitting the final study protocol to the FDA in March 2022, as previously announced. Biogen expects the first patient to enter screening in May 2022 and the trial's primary completion approximately four years after the study begins.

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

Sales of Aduhelm, Biogen's Alzheimer's disease drug, have fallen far short of expectations.

Biogen Files the Final Design for Aduhelm's Post-Approval Study

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 29, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and reminds investors of the April 8, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $200,000 investing in Biogen stock or options between...

Biogen Shareholder Update

Ionis Pharma

Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx) for C9orf72-associated amyotrophic lateral sclerosis (ALS). In this Phase 1 study, BIIB078 was generally well-tolerated.

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS) , did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies for all forms of this progressive and fatal neurodegenerative disease CAMBRIDGE, Mass. and CARLSBAD, Calif.

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

Viatris

Viatris Inc (NASDAQ:VTRS) is up 0.5% to trade at $10.94 at last check.

Viatris Subsidiary Wins in Court Against Biogen Patent

NEW YORK , March 23, 2022 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) common stock between June 7, 2021 and January 11, 2022, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of Massachusetts and alleges violations of the Securities Exchange Act of 1934.

BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)

This drugmaker is no stranger to controversy.

2 Red Flags for Biogen's Future

Scientists are criticizing the publication of results from late-stage trials of Aduhelm in a small and relatively unknown journal.

Biogen's Aduhelm Credibility Problem Deepens. Investors Are Paying the Price.

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer's Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease. The publication includes results from the primary, secondary and tertiary endpoints in the trials, as well as safety data and biomarker sub-studies.

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease

Philadelphia, Pennsylvania--(Newsfile Corp. - March 16, 2022) - Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities of Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) between June 7, 2021 and January 11, 2022 (the "Class Period"). If you purchased Biogen securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or...

Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022

Shares of Biogen Inc. BIIB, +1.85% gained 4.3% in premarket trading on Wednesday after the company announced new data for its Alzheimer's disease drug demonstrating reductions in amyloid beta plaques for 132 weeks and plasma p-tau181 for 128 weeks. The company also said in a news release that the clinical-trial data show that patients with lower plasma p-tau181 levels had less clinical decline.

Biogen's stock gains after sharing longer term data for its Alzheimer's disease

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM® (aducanumab-avwa) injection 100 mg/mL for intravenous use, patients in the long-term extension phase of the Phase 3 trials continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid beta plaques and plasma p-tau181. The data also show that in both Phase 3 trials, at 78 weeks, patients with reduced levels of plasma p-tau181 had less clinical decline than those whose plasma p-tau181 levels were not reduced.

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer's Disease in Patients Treated for More Than Two Years

CAMBRIDGE, Mass. and TOKYO, March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM® (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and losses. The royalty rate starts at 2% and reaches 8% when annual sales exceed $1 billion. Effective immediately, Biogen's existing final decision-making rights on ADUHELM have converted to sole decision making and commercialization rights worldwide. Overall, economic arrangements for both companies in 2022 are expected to remain materially unchanged with Eisai's share of expenses capped at an agreed amount for the costs related to development, commercialization, and manufacturing of ADUHELM for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM's economics beyond these royalties.

Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments

Advertising campaign aimed at expanding Medicare payment for Aduhelm

News for Biogen Stock (BIIB)